Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Future of DLBCL Therapy Hinges on Optimal Use of CAR T-Cell Therapy, Bispecifics, and Other Novel Strategies

June 26th 2025

Alexey Danilov, MD, PhD, highlights the importance of re-evaluating sequencing strategies amid a growing arsenal of targeted therapies in DLBCL.

CHMP Offers Positive Opinion for Zanubrutinib Tablet Formulation in B-Cell Malignancies

June 25th 2025

The EMA’s CHMP has recommended the approval of zanubrutinib tablets for B-cell malignancies.

Rusfertide Significantly Reduces Therapeutic Phlebotomy Necessity in Polycythemia Vera

June 25th 2025

Andrew Kuykendall, MD, discusses the utility of rusfertide in reducing therapeutic phlebotomy eligibility in patients with polycythemia vera.

FDA Grants Priority Review to Revumenib for Relapsed/Refractory NPM1-Mutant AML

June 25th 2025

Revumenib’s sNDA has received priority review from the FDA for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia.

Outcomes With Obe-Cel in ALL: An Age-Based Analysis of the FELIX Trial

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

Dissecting the Impact of Obe-Cel on the ALL Treatment Paradigm

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

Reviewing Current Standards in Paroxysmal Nocturnal Hemoglobinuria

June 24th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

UM171 Cell Therapy Earns Positive CHMP Opinion for Hematological Malignancies

June 20th 2025

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

Evolving Paradigms in Relapsed DLBCL: Part 2

June 20th 2025

Manali Kamdar, MD, discusses evolving treatment paradigms in diffuse large B-cell lymphoma.

BGB-16673 Displays a High ORR and Tolerability in Waldenström Macroglobulinemia

June 19th 2025

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test

June 19th 2025

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies

June 18th 2025

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

June 17th 2025

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

June 17th 2025

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Health Canada Approves Quizartinib Plus Chemotherapy for Newly Diagnosed FLT3-ITD+ AML

June 17th 2025

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma

June 16th 2025

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.

Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL

June 15th 2025

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.